Navigation Links
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016
Date:12/6/2016

LONDON, Dec. 6, 2016 /PRNewswire/ -- Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 2016, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.


Report Highlights


Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 3 and 1 respectively.Homozygous Familial Hypercholesterolemia (HoFH).

Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Download the full report: https://www.reportbuyer.com/product/4423655/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/homozygous-familial-hypercholesterolemia-hofh---pipeline-review-h2-2016-300374107.html


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
2. ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
3. Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
4. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
5. Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015
6. Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
7. Global Hypercholesterolemia Market 2014-2018
8. PCSK9 and Other Novel Hypercholesterolemia Drugs
9. Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease
10. Novelos Therapeutics Provides Product Pipeline Update
11. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... 2017 It should come as no surprise to ... in the midst of a crippling opioid epidemic. According to ... number of overdose deaths from opiate-based medications has quadrupled, Says, ... million dead from 2001 to 2015". During this time, the ... similarly quadrupled, drawing a compelling link between prescription and eventual ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful ... Carpal tunnel syndrome affects more than 8 million people a year. ... men. The common methods of treating CTS are painful surgery, the ... or gloves. ... CarpalAID is a clear patch worn on the palm of ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... Health, as medical director. Dr. Negrette has more than a decade of experience ... has worked closely with individuals fighting addictions, eating disorders, psychotic and manic conditions, ...
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University ... it produces the same kind of electrical energy that the body uses. , ... moving electrons. This flow of electrons out of the battery is generated by moving ...
(Date:7/24/2017)... ... 24, 2017 , ... Cosmetic Town, an online plastic surgery information community, announces ... on a daily basis. , The new video series will feature board-certified doctors ... their practices. , When asked about the new video series, the senior editor ...
(Date:7/24/2017)... IQUITOS, Peru (PRWEB) , ... July 24, 2017 ... ... plans for $1,000 total in scholarship awards to be awarded annually to and ... who demonstrate an interest in bringing awareness to Amazonian plant medicine. To apply ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly ... for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... long term skin conditions, including cancer. In the short term, overexposure to ...
Breaking Medicine News(10 mins):